| Field | Specification |
|---|---|
| Mfr No | |
| Cas No. | |
| Clonality | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
futermestotug (HB651336) is a research-grade recombinant antibody targeting CD152. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
Specifications
| Host Species | Human |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Target | CD152/CTLA4 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| UniProt | P16410 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy).
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Schwartz, JC. et al. (2001) Nature 410, 604-8. PMID: 11279501
2. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502
3. Teft, WA. et al. (2006) Annual review of immunology 24, 65-97. PMID: 16551244
4. Linsley, PS. et al. (1991) The Journal of experimental medicine 174, 561-9. PMID: 1714933
5. Zheng, Y. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 1683-91. PMID: 18641304
6. Ramagopal, UA. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E4223-E4232. PMID: 28484017
